Jacobs Levy Equity Management
SCLN

Jacobs Levy Equity Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Jacobs Levy Equity Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-24,100
Closed -$167K – 921
2015
Q3 		$167K Sell
24,100
-17,400
-42% -$149K ﹤0.01% 725
2015
Q2 		$408K Sell
41,500
-38,300
-48% -$349K 0.01% 602
2015
Q1 		$707K Buy
79,800
+37,100
+87% +$296K 0.01% 546
2014
Q4 		$374K Buy
42,700
+11,500
+37% +$93.1K 0.01% 645
2014
Q3 		$215K Buy
+31,200
New +$187K ﹤0.01% 734
2014
Q2 		– Sell
-24,970
Closed -$114K – 989
2014
Q1 		$114K Sell
24,970
-15,900
-39% -$76.8K ﹤0.01% 850
2013
Q4 		$206K Buy
+40,870
New +$197K ﹤0.01% 869

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's SCLN Position: Q4 2015 in Review

Jacobs Levy Equity Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2015, closing a stake of 24,100 shares — an estimated $167K sold.

Jacobs Levy Equity Management first reported a position in SCLN in Q4 2013 and held it in 7 quarters. The position peaked at $707K in Q1 2015. 133 funds tracked by Wall St. Rank hold SCLN as of Q4 2015.

  • Jacobs Levy Equity Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 24,100 Sciclone Pharmaceuticals Inc shares in Q4 2015, an estimated $167K.
  • Jacobs Levy Equity Management first reported a position in Sciclone Pharmaceuticals Inc in Q4 2013 and held it in 7 quarters.
  • Jacobs Levy Equity Management's Sciclone Pharmaceuticals Inc position peaked at $707K in Q1 2015.
  • 133 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2015.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2015, filed 16 Feb 2016.